Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Puma Biotechnology Inc
PBYI
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$10.85
-0.17
-1.54%
Últ. Act.: Oct 27, 6:57 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 9 días de ahora en jue nov 5th, después del cierre del mercado
Puma Biotechnology Financials
Puma Biotechnology (PBYI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est
Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.
Benzinga Newsdesk
PRO
Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est
Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate.
Benzinga Newsdesk
PRO
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 375 percent. This is a 26.67 percent increase over earnings of $0.15 per share from
Benzinga Newsdesk
PRO
Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est
Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3 million$20–$23
Benzinga Newsdesk
PRO
Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est
Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3 million$20–$23
Benzinga Newsdesk
PRO
Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 140 percent decrease over earnings of $0.10 per share from
Benzinga Newsdesk
